论文部分内容阅读
目的探讨美多巴联合司来吉兰治疗帕金森病患者临床效果及其安全性评价。方法本研究病例来源于2014年8月至2015年8期间我院收治的原发性帕金森病患者86例,依据随机数字表法分为观察组43例与对照组43例。观察组采用美多巴联合司来吉兰治疗,对照组仅采用美多巴治疗。两组疗程均为3个月。结果观察组总有效率(86.05%)高于对照组(67.44%)(P<0.05);两组Webster评分治疗后明显减少(P<0.05);观察组Webster评分治疗后低于对照组(P<0.05);两组MDRSPD评分治疗后明显减少(P<0.05);观察组MDRSPD评分治疗后低于对照组(P<0.05);两组均未见严重用药不良反应。结论美多巴联合司来吉兰治疗帕金森病患者临床效果显著,且安全可靠。
Objective To investigate the clinical effects and safety of metoparamin combined with selegiline in patients with Parkinson’s disease. Methods Totally 86 patients with primary Parkinson’s disease who were treated in our hospital from August 2014 to August 2015 were divided into observation group (43 cases) and control group (43 cases) according to random number table. The observation group was treated with gemcitabine and metoprolol, while the control group received only metoprolol. Two groups of treatment are 3 months. Results The total effective rate (86.05%) in the observation group was significantly higher than that in the control group (67.44%) (P <0.05). The Webster score decreased significantly in both groups after treatment (P <0.05) <0.05). The MDRSPD score decreased significantly in both groups after treatment (P <0.05). The MDRSPD score in the observation group was lower than that in the control group after treatment (P <0.05). No adverse drug reactions were observed in both groups. Conclusion The combination of metoprogin and selegiline in patients with Parkinson’s disease has significant clinical effect and is safe and reliable.